Adenosine Deaminase in CSF
Use
Adenosine deaminase (ADA) activity can be measured in cerebrospinal fluid (CSF) and is used for the diagnosis of various neurological conditions. Elevated levels of ADA in CSF may indicate conditions such as tuberculous meningitis or meningeal involvement in lymphoma or leukemia. The test aids clinicians in assessing these conditions, providing valuable information for diagnosis and management.
Special Instructions
Notify the laboratory of the specimen source on the requisition form to ensure proper processing. It is essential that specimens remain frozen during transport to maintain sample integrity. Any deviation from this protocol may compromise the test results.
Limitations
The test is specific to adenosine deaminase levels in CSF and does not evaluate other fluid types. Specimen handling and pre-analytical conditions, such as prolonged storage without freezing or exposure to non-leakproof containers, can impact test integrity. Moreover, other conditions that are not associated with elevated ADA levels may not be elucidated by this test, thus limiting its use to specific differential diagnoses in neuropathological evaluation.
New York Approved
Methodology
Automated Analyzer (Clinical Chemistry)
Biomarkers
LOINC Codes
- 35703-8
- 35703-8
Result Turnaround Time
1-8 days
Related Documents
For more information, please review the documents below
Specimen
Cerebrospinal Fluid
Volume
0.5 mL
Minimum Volume
0.2 mL
Container
Leak-proof container
Collection Instructions
Centrifuge CSF specimen at ambient temperature. Transfer 0.5 mL fluid (supernatant) into a sterile vial and freeze. Send frozen. Specimen must remain frozen until received at performing lab. Indicate source on requisition.
Causes for Rejection
Bronchoalveolar lavage (BAL), glass tubes, turbid specimens, whole blood
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 7 days |
| Frozen | 30 days |